Join our daily newsletter At The Bell to receive exclusive market insights
- Medibio will provide PwC Australia employees access to ilumen
- This announcement follows a successful program Medibio conducted for PwC in 2018
- ilumen aims to help and improve employees mental health
- PwC employees will have access to the program for 12 months
- Medibio is up 9.09 per cent and is selling shares for 1.2¢ apiece
Medibio has signed an agreement to provide access to ilumen to PwC Australia.
From October, PwC Australia employees will have access to ilumen for twelve months. This announcement follows a successful program Medibio conducted for PwC in 2018.
ilumen is a program that provides data-driven feedback to help employees improve their mental well-being.
The company believes that when you present employees with the right tools and make the effort to take appropriate measures towards their mental well-being, they perform better at the workplace.
Medibio Senior Vice President of Corporate Health Jennifer Solitario, is pleased to be able to work with PwC to offer their workforce a better understanding of their mental wellbeing.
“PwC is leading the way in implementing programs that assure, as much as possible, the wellbeing of their workforce,” Jennifer said.
“To that end, ilumenTM will provide PwC Australia management with de-identified aggregate data to better support and manage the mental wellbeing of their workforce,” she added.
ilumen will also offer participants with early screening for symptoms of depression, anxiety and stress.
PwC Chief People Officer Dorothy Hisgrove, says PwC’s people value the opportunity to know where they’re at with their mental health.
“Initiatives such as this program are helping us to ‘dial up’ the dialogue around mental wellbeing across the firm, and increase our people’s awareness of the support that’s available to them at PwC,” she said.
“This agreement further demonstrates the interest and the need that we are seeing from the market in a variety of geographies for this technology,” Medibio CEO David Kaysen said.
“We are focused on developing additional long-term agreements after other clients complete various pilot trials,” he added.
Medibio is up 9.09 per cent and is selling shares for 1.2¢ apiece at 10:04 am AEDT.
